natgillin/translations-raw huggingface dataset:
Posaconazole is also available as 40 mg/mL oral suspension and 300 mg concentrate for solution for infusion. 
Posakonazolje na voljo tudi kot peroralna suspenzija 40 mg/mlin300mgkoncentratzaraztopinozainfundiranje.
Each tablet contains 100 mg of posaconazole. 
Ena tableta vsebuje 100 mg posakonazola.
tongue oedema, face oedema 
edem jezika, edem obraza
How to take Posaconazole Accord 
Kako jemati zdravilo Posakonazol Accord
Rarely, more severe hepatic reactions with fatal outcomes have been reported. 
O hujših učinkih na jetra s smrtnim izidom so poročali redko.
24x1 gastro-resistant tablet 96x1 gastro-resistant tablet 
FARMACEVTSKA OBLIKA IN VSEBINA 24 gastrorezistentnih tablet 96 gastrorezistentnih tablet 24 x 1 gastrorezistentna tableta 96 x 1 gastrorezistentna tableta
Concomitant use of posaconazole and rifabutin and similar inducers (e.g. rifampicin) should be avoided unless the benefit to the patient outweighs the risk. 
Sočasni uporabi posakonazola in rifabutina ter podobnih induktorjev (npr. rifampicina) se je treba izogibati, razen če korist za bolnika odtehta tveganje.
breast pain 
bolečine v dojkah
cerebrovascular accident, encephalopathy, peripheral neuropathy, syncope 
cerebrovaskularni inzult, encefalopatija, periferna nevropatija, sinkopa
Electrolyte disturbances, especially those involving potassium, magnesium or calcium levels, should be monitored and corrected as necessary before and during posaconazole therapy. 
Bolnika je treba spremljati, da bi ugotovili morebitne motnje ravnovesja elektrolitov, zlasti motnje koncentracije kalija, magnezija ali kalcija, in jih po potrebi odpraviti pred ali med zdravljenjem s posakonazolom.
Posaconazole increased Cmax and AUC of tacrolimus (0.05 mg/kg body weight single dose) by 121% and 358%, respectively. 
Posakonazolje povečal Cmaxtakrolimusa(enkratni odmerek0,05 mg/kg telesne mase) za121 %innjegovo
As observed with other azole antifungal agents, these effects on reproduction were considered to be due to a treatment-related effect on steroidogenesis. 
Tako kot pri drugih azolskih antimikotikih so ti učinki na razmnoževanje štelizaposledico z zdravljenjempovezanegaučinkanasteroidogenezo.
Serial PK samples were collected on Day 1 and at steady-state on Day 8 for all Part 1 subjects and a subset of Part 2 subjects. 
Zaporedne farmakokinetične vzorce so vzeli 1.dan in v stanju dinamičnega ravnovesja 8. dan, in sicer vsem preiskovancem iz dela 1 in podskupini preiskovancev iz dela 2.
Posaconazole oral suspension 
Peroralna suspenzija posakonazola
Summary of posaconazole oral suspension studies 
Povzetek študij s peroralno suspenzijo posakonazola
ANNEX II A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA
Efavirenz (400 mg once a day) decreased the Cmax and AUC of posaconazole by 45% and 50%, respectively. 
Efavirenz(400 mg enkrat na dan) je zmanjšalCmaxposakonazola za 45 %, njegovo AUC paza 50
Stevens Johnson syndrome, vesicular rash Musculoskeletal and connective tissue disorders Uncommon: 
Stevens-Johnsonov sindrom, vezikularen izpuščaj Bolezni mišično-skeletnega sistema in vezivnega tkiva
Concomitant use of posaconazole and phenytoin and similar inducers (e.g. carbamazepine, phenobarbital, primidone) should be avoided unless the benefit to the patient outweighs the risk. 
50 %.Sočasni uporabi posakonazola in fenitoina ter podobnih induktorjev (npr. karbamazepina, fenobarbitala, primidona) se je treba izogibati, razen če korist za bolnika odtehta tveganje.
Maximum duration of exposure to the tablet formulation was shorter than with the oral suspension. 
Najdaljša izpostavljenost zdravilu v obliki tablet je bila krajša kot izpostavljenost zdravilu v obliki peroralne suspenzije.
Monitoring of hepatic function 
Spremljanje delovanja jeter
Repeat dose administration of fosamprenavir (700 mg twice daily x 10 days) decreased the Cmax and AUC of posaconazole oral suspension (200 mg once daily on the 1st day, 200 mg twice daily on the 2nd day, then 400 mg twice daily x 8 Days) by 21% and 23%, 
10dni)sta se Cmaxin AUC posakonazola vobliki peroralne suspenzije (200 mg enkrat nadan prvi dan,200 mg dvakrat na dan drugi dan, nato 400 mg dvakrat na dan 8 dni) zmanjšali za 21 % oz. 23 %.
The safety of posaconazole oral suspension has been assessed in > 2,400 patients and healthy volunteers enrolled in clinical trials and from post-marketing experience. 
Varnost peroralne suspenzije posakonazola so ocenili pri > 2.400 bolnikih in zdravih prostovoljcih,
Dose adjustment of benzodiazepines metabolised by CYP3A4 should be considered (see section 4.5). 
Razmisliti je treba o prilagoditvi odmerka benzodiazepinov, ki se presnavljajo s CYP3A4 (glejtepoglavje 4.5).
11 of 24 patients who had proven or probable fusariosis were successfully treated with posaconazole oral suspension 800 mg/day in divided doses for a median of 124 days and up to 212 days. 
11 od 24 bolnikov, ki so dokazano ali verjetno imeli fuzariozo, so uspešno zdravili s peroralno suspenzijo posakonazola 800 mg/dan v deljenih odmerkih.
Patients were enrolled in a non-comparative pharmacokinetic and safety trial of posaconazole tablets when given as antifungal prophylaxis. 
Bolnike so vključili v neprimerjalno preskušanje farmakokinetike in varnosti tablet posakonazola, uporabljenih za antimikotično profilakso.
If concomitant administration is required, close monitoring for breakthrough fungal infections is recommended. 
Če je potrebna sočasna uporaba, je bolnike priporočljivoskrbnospremljatigledeprebijajočih glivnih okužb.
Study 316 was a randomised, double-blind trial of posaconazole oral suspension (200 mg three times a day) versus fluconazole capsules (400 mg once daily) in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease (GVHD). 
Študija316 je bila randomizirano, dvojno slepo preskušanje s peroralno suspenzijo posakonazola (200 mgtrikratnadan) v primerjavi s kapsulamiflukonazola(400mgenkratnadan)pribolnikihpoalogenski transplantaciji hematopoetskih matičnih celic z reakcijo presadka proti gostitelju (GVHD -graftversus-host disease).
pancreatitis, abdominal distension, enteritis, epigastric discomfort, eructation, gastrooesophageal reflux disease, oedema mouth 
pankreatitis, abdominalna distenzija, enteritis, nelagodje v epigastriju, spahovanje, gastroezofagealna refluksna bolezen, edem v ustih
Posaconazole plasma concentrations following administration of posaconazole tablets may increase over time in some patients (see section 5.2). 
Koncentracije posakonazola vplazmi se lahko po uporabi tablet pri nekaterih bolnikihsčasoma povečajo (glejte poglavje 5.2).
Following single-dose administration of posaconazole oral suspension, there was no effect of mild and moderate renal impairment (n=18, Cl cr ≥ 20 mL/min/1.73 m2) on posaconazole pharmacokinetics; therefore, no dose adjustment is required. 
Poenkratnemodmerkuperoralnesuspenzijeposakonazolablagainzmernaokvaraledvic(n= 18,očistekkreatinina≥20 ml/min/1,73 m2)nistavplivalinafarmakokinetikoposakonazola,zatoprilagoditev odmerka ni potrebna.
Patients were immunocompromised with underlying conditions including haematological malignancy, neutropenia post-chemotherapy, GVHD, and post HSCT. 
Bolniki so imeli oslabljen imunski sistem in osnovne bolezni, med njimi hematološke malignome, nevtropenijo po kemoterapiji, GVHD ali so bili po presaditvi hematopoetskih matičnih celic (HSCT).
b: In 1899 this was the period from randomization to last dose of study medicinal product plus 7 days; in 316 
V študiji 1899 je bilo to obdobje od randomizacije do zadnjega odmerka preučevanega zdravila plus 7dni,
Rifamycin antibacterials (rifampicin, rifabutin), certain anticonvulsants (phenytoin, carbamazepine, phenobarbital, primidone), and efavirenz 
Rifamicinski antibiotiki (rifampicin, rifabutin), določeni antikonvulzivi (fenitoin,
The primary efficacy endpoint was the incidence of proven/probable IFIs as determined by an independent, blinded external expert panel during the on-treatment period. 
Primarni opazovani dogodek učinkovitosti je bila pojavnostdokazanihoziromaverjetnihinvazivnihglivnih okužb, kijihjeugotavljala neodvisna skupina zunanjih strokovnjakov na slep način medobdobjem zdravljenja.
Study 1899 was a randomised, evaluator-blinded study of posaconazole oral suspension (200 mg three times a day) versus fluconazole suspension (400 mg once daily) or itraconazole oral solution (200 mg twice a day) in neutropenic patients who were receiving cytotoxic chemotherapy for acute myelogenous leukaemia or myelodysplastic syndromes. 
Študija 1899 je bila randomizirana, za ocenjevalce slepa študija, ki je primerjala uporabo peroralne suspenzije posakonazola (200 mg trikrat na dan) in suspenzije flukonazola (400 mgenkratnadan)aliperoralne raztopine itrakonazola (200 mg dvakrat na dan) pri bolnikih z nevtropenijo, ki so prejemalicitotoksično kemoterapijo zaradi akutne mieloične levkemije ali mielodisplastičnih sindromov.
If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before taking Posaconazole Accord. 
Če kaj od naštetega velja za vas (ali če ste negotovi), se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden začnete jemati zdravilo Posakonazol Accord.
Posaconazole is highly protein bound (> 98%), predominantly to serum albumin. 
Posakonazolje v velikimerivezannabeljakovine(>98%),predvsemnaserumskialbumin.
Cav quartile analyses of pivotal patient studies with posaconazole tablet and oral suspension Posaconazole tablet 
Preglednica 3.Analiza kvartilov Cav ključnih študij pri bolnikih z uporabo tablet in peroralne suspenzije posakonazola
A. fumigatus 
A. fumigatus A. flavus
hypersensitivity reaction 
preobčutljivostna reakcija
If posaconazole is used concomitantly with CYP3A4 substrates that are administered orally, and for which an increase in plasma concentrations may be associated with unacceptable adverse reactions, plasma concentrations of the CYP3A4 substrate and/or adverse reactions should be closely monitored and the dose adjusted as needed. 
Med sočasno uporabo posakonazola in peroralnih substratov CYP3A4, pri katerih lahko povečanje plazemske koncentracije spremljajo nesprejemljivi neželeni učinki, je treba skrbno spremljati plazemske koncentracije substrata
convulsions, neuropathy, hypoaesthesia, tremor, aphasia, insomnia 
konvulzije, nevropatija, hipestezija, tremor, afazija,
Plasma exposure resulting from the tablet formulation was higher than observed with the oral suspension. 
Plazemska izpostavljenost zdravilu iz tablet je bila večja od tiste, ki so jo opazili pri peroralni suspenziji.
Do not take Posaconazole Accord if you are taking any of the following: - terfenadine (used to treat allergies) - astemizole (used to treat allergies) - cisapride (used to treat stomach problems) - pimozide (used to treat symptoms of Tourette's and mental illness) - halofantrine (used to treat malaria) - quinidine (used to treat abnormal heart rhythms). 
- terfenadin (za zdravljenje alergij) - astemizol (za zdravljenje alergij) - cisaprid (za zdravljenje težav z želodcem) - pimozid (za zdravljenje simptomov Tourettovega sindroma in duševnih bolezni) - halofantrin (za zdravljenje malarije)
Caution should be used when prescribing Posaconazole Accord to patients with hypersensitivity to other azoles. 
Pripredpisovanju zdravila Posakonazol Accord bolnikom, preobčutljivim na druge azole, je potrebna previdnost.
Refractory invasive fungal infections (IFI)/patients with IFI intolerant to 1st line therapy 
Rezistentne invazivne glivne okužbe/bolniki z rezistentno glivnookužbo,kineprenašajo zdravljenja 1. izbora
- inability to sleep (insomnia) - being completely or partially unable to talk - swelling of the mouth - abnormal dreams, or difficulty sleeping - problems with co-ordination or balance - mucosal inflammation - stuffy nose - difficulty breathing - chest discomfort - feeling bloated - mild to severe nausea, vomiting, cramps and diarrhoea, usually caused by a virus, stomach pain - belching - feeling jittery 
- zastajanje vode (edemi) - težave z menstruacijo (nenormalna krvavitev iz nožnice) - nezmožnost zaspati (nespečnost) - popolna ali delna nezmožnost govorjenja - otekanje vustih - nenormalne sanje, težave s spanjem - težave z usklajenostjo gibov (koordinacijo) ali ravnotežjem - vnetje sluznice - zamašen nos - težko dihanje - nelagodje v prsnem košu - občutek napihnjenosti
The addition of posaconazole to therapy with atazanavir or with atazanavir plus ritonavir was associated with increases in plasma bilirubin levels. 
Dodatek posakonazola med zdravljenjem z atazanavirjem oziroma zatazanavirjem inritonavirjemje bilpovezan s povečanjemkoncentracijebilirubina vplazmi.
Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC code: J02AC04 
Farmakoterapevtska skupina: antimikotiki za sistemsko zdravljenje, derivati triazola.
Posaconazole tablet and oral suspension safety 
Varnost tablet in peroralne suspenzije posakonazola
Both doses of posaconazole increased Cmax and AUC of oral midazolam (2 mg single oral dose) by 2.2 and 4.5-fold, respectively. 
Oba odmerkaposakonazola sta povečala Cmaxperoralno uporabljenegamidazolama (enkratniperoralni odmerek 2 mg) za 2,2-krat in njegovo AUC za 4,5-krat.
The pharmacokinetics of posaconazole oral suspension have been evaluated in paediatric patients. 
Pri pediatričnih bolnikih so ocenili farmakokinetiko peroralne suspenzije posakonazola.
Phenytoin (200 mg once a day) decreased the Cmax and AUC of posaconazole by 41% and 50%, respectively. 
Fenitoin(200 mg enkrat na dan) je zmanjšalCmaxposakonazola za 41 %, njegovo AUC paza
Clinically significant interactions resulting in hospitalisation and/or posaconazole discontinuation were reported in clinical efficacy studies. 
V študijah klinične učinkovitosti so poročali o kliničnopomembnihinterakcijah, ki so zahtevale sprejem v bolnišnico in/ali ukinitev posakonazola.
If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Posaconazole Accord. 
Če kaj od naštetega velja za vas (ali če ste negotovi), se posvetujte z zdravnikom ali farmacevtom, preden začnete jemati zdravilo Posakonazol Accord.
Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with serious adverse reactions (see section 4.4). 
Sočasna uporaba azolskih antimikotikov, vključno s posakonazolom, in vinkristina je bila povezana zresnimineželenimi učinki (glejte poglavje
Due to the risk of prolonged sedation and possible respiratory depression co-administration of posaconazole with any benzodiazepines metabolised by CYP3A4 (e.g. midazolam, triazolam, alprazolam) should only be considered if clearly necessary. 
Zaradi tveganja pojava dolgotrajne sedacije in morebitne depresije dihanja lahko sočasna uporaba posakonazola in katerega koli benzodiazepina, ki se presnavlja s CYP3A4 (npr. midazolam,
Breast-feeding must be stopped on initiation of treatment with posaconazole. 
Ob uvedbi zdravljenja s posakonazolom je treba prenehati zdojenjem.
There are currently insufficient data to set clinical breakpoints for Aspergillus spp. 
Trenutno ni dovolj podatkov za določitev kliničnih mejnih vrednosti zaAspergillus spp.Vrednosti ECOFF niso enake kliničnim mejnim vrednostim.
paresthesia, dizziness, somnolence, headache, dysgeusia 
parestezija, omotica, zaspanost, glavobol, disgevzija
The mean duration of therapy was 80 days for posaconazole and 77 days for fluconazole. 
dni in s flukonazolom 77 dni.
Glucose concentrations decreased in some healthy volunteers when glipizide was co-administered with posaconazole. 
Med sočasno uporabo glipizida in posakonazola se je pri nekaterih zdravih prostovoljcih znižala koncentracija glukoze.
Of the circulating metabolites, the majority are glucuronide conjugates of posaconazole with only minor amounts of oxidative (CYP450 mediated) metabolites observed. 
Posakonazol v obtoku nimanobenegaglavnegapresnovkainniverjetno,dabizaviralciencimov CYP450 vplivali nanjegovokoncentracijo.Odpresnovkov v obtoku je večina glukuronidnihkonjugatov posakonazola, opazili pa so le majhne količine oksidativnih presnovkov (presnova posredovana s CYP450).
thrombocytopenia, leukopenia, anaemia, eosinophilia, lymphadenopathy, splenic infarction 
trombocitopenija, levkopenija, anemija, eozinofilija,
There is no special treatment available in the case of overdose with posaconazole. 
V primeru prevelikega odmerjanja posakonazola ni na voljo nobenega posebnega zdravljenja.
Cases of elevated ciclosporin levels resulting in serious adverse reactions, including nephrotoxicity and one fatal case of leukoencephalopathy, were reported in clinical efficacy studies. 
V študijah klinične učinkovitosti so poročali o primerihpovečane koncentracije ciklosporina, ki je povzročila resne neželene učinke, vključno znefrotoksičnostjo in enim smrtnim primerom levkoencefalopatije.
pyrexia (fever), asthenia, fatigue 
pireksija (zvišana telesna temperatura), astenija, utrujenost
The primary efficacy endpoint was the incidence of proven/probable IFIs at 16 weeks post-randomization as determined by an independent, blinded external expert panel. 
Primarni opazovani dogodek učinkovitosti je bila pojavnost dokazanihoziromaverjetnihinvazivnihglivnihokužb16tednovporandomizaciji,kijih jeugotavljalaneodvisna skupina zunanjih strokovnjakov na slep način.
Frequent monitoring for adverse reactions and toxicity related to calcium channel blockers is recommended during co-administration with posaconazole. 
Medsočasnouporabo s posakonazolom je priporočljivo pogosto spremljanje gledeneželenihučinkovin toksičnosti, povezanih z zaviralci kalcijevih kanalčkov.
Q3 
QTc.
Tell your doctor if you are or think you are pregnant before you start to take Posaconazole Accord. 
Če ste noseči ali menite, da bi lahko bili noseči, se posvetujte z zdravnikom, preden vzamete zdravilo Posakonazol Accord.
Liver function tests should be evaluated at the start of and during the course of posaconazole therapy. 
Testedelovanjajeterje treba opraviti na začetku zdravljenja s posakonazolom in med zdravljenjem z njim.
Co-administration of posaconazole with CYP3A4 substrates may result in large increases in exposure to CYP3A4 substrates as exemplified by the effects on tacrolimus, sirolimus, atazanavir and midazolam below. 
PosakonazoljemočanzaviralecCYP3A4.SočasnauporabaposakonazolainsubstratovCYP3A4lahko zelo poveča izpostavljenost tem substratom, kot kažejo spodaj opisani učinki na takrolimus, sirolimus,
Pulmonary phospholipidosis resulting in dilatation and obstruction of the alveoli was observed in the 2-year study in rats. 
V2-letni študiji na podganah so opažali pljučno fosfolipidozo, ki je povzročila dilatacijo inobstrukcijo alveolov.
Following a single dose administration of 300 mg posaconazole tablets after a high fat meal to healthy volunteers, the AUC0-72 hours and Cmax were higher compared to administration under fasted condition (51% and 16% for AUC0-72 hours and Cmax respectively). 
Po enkratnem odmerku 300 mgposakonazola v tabletahpozelomastnemobrokustabiliprizdravihprostovoljcih AUC0-72urinCmaxvečji kotpouporabi natešče (AUC0-72 ur51%in Cmax16%).
H2 receptor antagonists and proton pump inhibitors No clinically relevant effects were observed when posaconazole tablets are concomitantly used with antacids, H2-receptor antagonists and proton pump inhibitors. 
Antagonistireceptorjev H2in zaviralci protonske črpalke Medsočasno uporabo tablet posakonazola in antacidov, antagonistov receptorjev H2inzaviralcevprotonskečrpalkenisoopazilikliničnopomembnihučinkov.Med sočasno uporabo tabletposakonazolain antacidov, antagonistov receptorjev H2in zaviralcev protonske črpalkeprilagoditevodmerka tablet posakonazola ni potrebna.
Talk to your doctor or pharmacist before taking Posaconazole Accord - if you have had an allergic reaction to another antifungal medicine such as ketoconazole, 
- če ste imeli alergijsko reakcijo na kakšno drugo protiglivno zdravilo, npr. na ketokonazol,
Gastro-resistant tablet 
FARMACEVTSKA OBLIKA gastrorezistentna tableta
Hepatic reactions (e.g. mild to moderate elevations in ALT, AST, alkaline phosphatase, total bilirubin and/or clinical hepatitis) have been reported during treatment with posaconazole. 
Med zdravljenjem s posakonazolom so poročali o učinkih na jetra (npr. blago do zmerno zvišanje ALT, AST, alkalne fosfataze, celokupnega bilirubina in/ali klinični hepatitis).
There are limited pharmacokinetic data in patients with severe gastrointestinal dysfunction (such as severe diarrhoea). 
Motnje v delovanju prebavil Zabolnike s hudimi motnjami v delovanju prebavil (npr. s hudo drisko) je na voljo malofarmakokinetičnih podatkov.
Fixed-time periodc 
Določenočasovno obdobjec
Steady-state plasma concentrations are attained by Day 6 at the 300 mg dose (once daily after twice daily loading dose at Day 1). 
Plazemska koncentracija v stanjudinamičnega ravnovesja je dosežena do 6. dne pri uporabi 300 mgodmerka(enkrat na dan pozačetnem odmerku dvakrat na dan 1. dan).
No effects on electrocardiograms, including QT and QTc intervals, were seen in a repeat dose safety pharmacology study in monkeys at maximal plasma concentrations 8.5-fold greater than the concentrations obtained at therapeutic doses in humans. 
V farmakološki študiji varnosti ponavljajočih se odmerkov na opicah pri največjih koncentracijah v plazmi,kisobile8,5-krat večje od koncentracij, doseženih med uporabo terapevtskih odmerkov pričloveku, na elektrokardiogramih (vključno zintervaloma QT in QTc) niso opazili nobenih učinkov.
rash, pruritis 
izpuščaj, pruritus
Do not take Posaconazole Accord if you are pregnant unless you are told to by your doctor. 
Če ste noseči, ne jemljite zdravila Posakonazol Accord, razen če vam to naroči zdravnik.
If you get any side effects, talk to your doctor or pharmacist or nurse. 
Če opazite katerega koli izmed neželenih učinkov, se posvetujte z zdravnikom ali farmacevtom ali medicinsko sestro.
Neutropenia 
nevtropenija
No overall differences in safety were observed between the geriatric patients and younger patients; therefore, no dosage adjustment is recommended for geriatric patients. 
V celoti niso ugotovilirazlik v varnostimedgeriatričnimibolnikiinmlajšimi bolniki,zatogeriatričnimbolnikomodmerka ni treba prilagoditi.
In another study in healthy volunteers, repeat dose administration of posaconazole oral suspension (200 mg twice daily for 7 days) increased the Cmax and AUC of intravenous midazolam (0.4 mg single dose) by an average of 1.3- and 4.6-fold (range 1.7 to 6.4-fold), respectively; Posaconazole oral suspension 400 mg twice daily for 7 days increased the intravenous midazolam Cmax and AUC by 1.6 and 6.2-fold (range 1.6 to 7.6-fold), respectively. 
(200 mg dvakrat na dan7dni) povečala Cmaxintravensko uporabljenegamidazolama(enkratni odmerek 0,4 mg) v povprečju za 1,3-krat, njegovo AUC pa za 4,6-krat (razpon od 1,7-kratdo 6,4krat).Peroralnasuspenzijaposakonazola v odmerku400mgdvakratnadan 7dni je povečalaCmaxintravenskouporabljenegamidazolamaza1,6-krat in njegovo AUC za 6,2-krat (razpon od 1,6-krat do 7,6-krat).
Similarly, in the prophylaxis studies, the mean steady-state posaconazole average concentration (Cav) 
Podobno je bila v študijah profilaktične uporabe povprečna koncentracija posakonazola v stanju dinamičnega ravnovesja
Based on Kaplan-Meier estimates, the probability of survival up to day 100 after randomization, was significantly higher for posaconazole recipients; this survival benefit was demonstrated when the analysis considered all causes of death (P=0.0354) as well as IFI-related deaths (P = 0.0209). 
Napodlagi Kaplan-Meierjevihocenjebilaverjetnostpreživetjado 100. dne po randomizaciji značilnovečja pri bolnikih, ki so prejemali posakonazol.Takoristenvplivnapreživetjesodokazali,koso vanaliziupoštevalivsevzrokesmrti(p = 0,0354), pa tudi smrti, povezane z invazivno glivno okužbo(p =